Last reviewed · How we verify
atorvastatin and clopidogrel
This combination reduces cholesterol levels and prevents blood clots by inhibiting HMG-CoA reductase and platelet aggregation, respectively.
This combination reduces cholesterol levels and prevents blood clots by inhibiting HMG-CoA reductase and platelet aggregation, respectively. Used for Secondary prevention of cardiovascular events in patients with acute coronary syndrome, Prevention of stent thrombosis following percutaneous coronary intervention, Reduction of cardiovascular risk in patients with established coronary artery disease.
At a glance
| Generic name | atorvastatin and clopidogrel |
|---|---|
| Sponsor | Ospedale Misericordia e Dolce |
| Drug class | Statin and P2Y12 platelet inhibitor combination |
| Target | HMG-CoA reductase and P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Atorvastatin is a statin that blocks HMG-CoA reductase, reducing LDL cholesterol synthesis and lowering cardiovascular risk. Clopidogrel is a P2Y12 platelet inhibitor that prevents thrombotic events by reducing platelet aggregation. Together, they provide complementary cardioprotective effects through lipid lowering and antiplatelet mechanisms.
Approved indications
- Secondary prevention of cardiovascular events in patients with acute coronary syndrome
- Prevention of stent thrombosis following percutaneous coronary intervention
- Reduction of cardiovascular risk in patients with established coronary artery disease
Common side effects
- Muscle pain or myalgia
- Elevated liver enzymes
- Bleeding
- Dyspepsia
- Headache
Key clinical trials
- Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation (PHASE4)
- to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban (PHASE1)
- A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI) (PHASE3)
- Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Artery Stenosis Patients: A Cohort Study
- Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Moderate and Moderate-to-severe Stroke (PHASE3)
- Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke (PHASE3)
- Traditional Chinese Medicine Intervention for Ischemic Cerebrovascular Disease and Diabetes Mellitus: An Efficacy Comparative Study (PHASE4)
- Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- atorvastatin and clopidogrel CI brief — competitive landscape report
- atorvastatin and clopidogrel updates RSS · CI watch RSS
- Ospedale Misericordia e Dolce portfolio CI